Ensysce Biosciences - חוב לטווח קצר של החברה ENSC

Ensysce Biosciences (ENSC) focuses on developing systems that eliminate drug overdose by ensuring medications are activated exclusively within the gastrointestinal tract. The company's technological edge is based on the unique TAAP method, which blocks the non-target use of opioids. Current price action, where the indicator stands at 0.00, is supported by management's steady course toward aligning research with stringent FDA standards to preserve the patent portfolio.

To minimize fundamental risks, investors should select assets with a controlled amount of liabilities due for repayment within twelve months. This metric aggregates all current loans and borrowings, allowing a real-time assessment of Ensysce Biosciences (ENSC) liquidity when financing robotic chemical tests without increasing operational personnel expenses through the short-term debt balance.